Benitec Biopharma Inc. (BNTC)
BNTCNASDAQ-CMBiotechnology: Pharmaceutical Preparations
$9.90
+0.3900 (+4.10%) today
Closed, Nov 9, 4:00 PM ET
- Market cap
- $344.36m
- P/E
- –
- EPS, last 4 quarters
- $-0.9800
- Dividend yield
- –
- Day range
- –
- 52-week range
- $7.89 to $14.39
- Average volume
- 172.9k
- Previous close
- $9.51
Analysts
5 coveringBuy5 buy, 0 hold, 0 sell
Targets a year out average $22.00, +122.2% from here
Earnings
next estimate $-0.3000Next report Nov 13, 2026
Sep 2025
+37.1%
Dec 2025
-13.0%
Mar 2026
+11.1%
Jun 2026
0.0%
estimate reported, and the surprise
Financials
| Quarter | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
| Revenue | – | – | – | – |
| Gross profit | – | – | – | – |
| Operating income | -$9.80m | -$13.38m | -$13.58m | -$14.43m |
| Net income | -$8.96m | -$11.84m | -$11.94m | -$12.81m |
News
8 latest- Weekly Buzz: ABBV, PFE Win FDA Nod; ARTV Slashes Jobs; DAVI, SGRY Strike Deals RTTNews · Oct 30, 2026
- Benitec Biopharma Inc. Announces Positive Interim Phase 1b/2a Results for High Dose BB-301Fintel · Oct 28, 2026
- Benitec's BB-301 Shows Swallowing Improvements In Phase 1b/2a Muscle Disorder Trial RTTNews · Oct 28, 2026
- After Plunging 23.9% in 4 Weeks, Here's Why the Trend Might Reverse for Benitec Biopharma (BNTC)Zacks · Sep 25, 2026
- Benitec Biopharma FY26 Net Loss Widens; BB-301 Interim Data Due In October RTTNews · Sep 15, 2026
- Evercore ISI Group Initiates Coverage of Benitec Biopharma (BNTC) with Outperform RecommendationFintel · May 12, 2026
- Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial RTTNews · Mar 9, 2026
- Weekly Buzz: LYRA Slashes Jobs; FDA Okays FBIO's ZYCUBO; BSX To Acquire PEN; BCTX On Watch RTTNews · Jan 16, 2026
The company
Benitec Biopharma Inc. (NASDAQ: BNTC) is a clinical-stage biotechnology company developing disease-modifying genetic medicines designed to improve the lives of people with life-threatening, genetically defined diseases. The company's proprietary 'Silence and Replace' DNA-directed RNA interference (ddRNAi) platform combines RNA interference, or RNAi, with gene therapy to create medicines designed to facilitate sustained silencing of disease-causing genes and simultaneous delivery of replacement genes that restore normal cellular function following a single administration. The company's lead investigational candidate, BB-301, is the first and only disease-modifying genetic medicine in clinical development for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD)-related dysphagia.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ-CM
- Region
- North America
- Website
- benitec.com
Often looked at with it
Figures from Yahoo, Nasdaq (Zacks consensus) and Lighter. Stocks can be minutes behind. Nothing here is advice.